GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 51.5% in December

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 1,514,630 shares, a decline of 51.5% from the December 15th total of 3,124,146 shares. Approximately 5.1% of the shares of the company are short sold. Based on an average daily trading volume, of 6,248,406 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 6,248,406 shares, the days-to-cover ratio is presently 0.2 days. Approximately 5.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

GOVX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Wednesday, October 8th. D. Boral Capital dropped their price target on GeoVax Labs from $225.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $187.50.

GeoVax Labs Price Performance

NASDAQ:GOVX traded up $0.14 during mid-day trading on Friday, hitting $2.99. The company’s stock had a trading volume of 234,250 shares, compared to its average volume of 231,065. The business’s fifty day moving average is $7.48 and its two-hundred day moving average is $13.32. The stock has a market cap of $3.59 million, a price-to-earnings ratio of -0.08 and a beta of 3.67. GeoVax Labs has a 1 year low of $2.61 and a 1 year high of $57.50.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. Analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs during the 1st quarter worth approximately $27,000. Hudson Bay Capital Management LP purchased a new stake in GeoVax Labs during the third quarter worth $47,000. Armistice Capital LLC purchased a new stake in GeoVax Labs during the third quarter worth $253,000. Finally, Sabby Management LLC acquired a new stake in GeoVax Labs during the third quarter valued at $313,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.